NeuroDiscovery makes market debut
Monday, 15 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
NeuroDiscovery's IPO raised AUD$1.5 million through the issue of 36 million shares, and the company has finalised purchase of UK-based NeuroSolutions, which has a mature pipeline of programs for the treatment of pain.
"We are very pleased that we have been able to buy NeuroSolutions and welcome the University of Warwick as our major shareholder. As this is the first successful spin-out of the university we look forward to working with them in the next few years." said NeuroDiscovery chairman David McAuliffe.
At the time of writing, shares were trading at $0.20.
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
Over-the-counter pain relievers may improve concussion recovery
People who take over-the-counter pain relievers after a concussion may recover faster than those...